Boundless Bio, Inc. (BOLD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BOLD currently has 22.4M outstanding shares. with moderate dilution risk from 9.6M authorized shares representing 42.9% potential dilution. The company has minimally diluted shareholders by 1.85% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
10-Q filing | 22.4M shares outstanding |
22M | 9.6M |
| Mar 09, 2026 |
10-K filing | 22.4M shares outstanding |
22M | 9.6M |
| Nov 05, 2025 |
10-Q filing | 22.4M shares outstanding |
22M | 9.6M |
| Aug 05, 2025 |
10-Q filing | 22.4M shares outstanding |
22M | 9.6M |
| May 09, 2025 |
10-Q filing | 22.3M shares outstanding |
22M | 9.6M |
| Apr 01, 2025 |
S-3 filing: The company is filing an S-3 to offer and sell up to $400 million in common stock, preferred stock, and debt securities from time to time. They intend to use the net proceeds from this offering to fund the research and development of our ecDTx and for working capital and general corporate purposes, including our ecDNA diagnostic and Spyglass platform. |
22M | 9.6M |
| Mar 27, 2025 |
10-K filing | 22.3M shares outstanding |
22M | 0 |
| Nov 07, 2024 |
10-Q filing | 22.3M shares outstanding |
22M | 0 |
| Aug 12, 2024 |
10-Q filing | 22.0M shares outstanding |
22M | 0 |
| May 13, 2024 |
10-Q filing | 22.3M shares outstanding |
22M | 0 |
| Mar 21, 2024 |
S-1/A filing: This S-1/A filing details an underwriting agreement where Boundless Bio, Inc. proposes to issue and sell common stock to underwriters, with options for additional shares. |
N/A | 0 |
| Mar 06, 2024 |
S-1 filing: This S-1 filing outlines various scenarios for issuing Common Stock, Options, and Convertible Securities, including dividends, stock splits, employee compensation, acquisitions, strategic partnerships, and public offerings. |
N/A | 0 |